Turning Point Therapeutics
Turning Point Therapeutics, now integrated with Bristol Myers Squibb, specializes in precision oncology through structure‑based drug design.
Company facts
- Founded
- 2013
- Employees
- 500
- Headquarters
- United States
- Type
- Enterprise
About
Turning Point Therapeutics, now integrated with Bristol Myers Squibb, specializes in precision oncology through structure‑based drug design. The company focuses on developing targeted therapies that address oncogenic drivers and resistance mechanisms in cancers such as NSCLC, leveraging expertise in NTRK, ROS1, ALK, SRC, FAK, JAK2, and related pathways. By combining its innovative platform with BMS’s resources, Turning Point aims to deliver next‑generation medicines that improve outcomes for patients with metastatic and treatment‑resistant tumors, offering a compelling environment for scientists and professionals dedicated to advancing cancer therapeutics.